Enclomiphene and Halotestin Interaction

Avoid
Mechanism-based 64% confidence

Enclomiphene and Halotestin have a potentially harmful interaction with 64% confidence. Both Enclomiphene and Halotestin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

Halotestin

Oral Anabolic Steroid | Extreme Strength & Aggression

Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue.

Half-life: ~9.5 hours Typical dose: 10-20 mg/day anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, Halotestin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Enclomiphene, Halotestin). Monitor accordingly.

Frequently Asked Questions

Can I take Enclomiphene with Halotestin?

Combining Enclomiphene with Halotestin is not recommended. Both Enclomiphene and Halotestin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Halotestin safe together?

This combination carries significant risk. Both Enclomiphene and Halotestin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Halotestin?

Both Enclomiphene and Halotestin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Halotestin?

Enclomiphene has a half-life of ~10 hours and Halotestin has a half-life of ~9.5 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs Halotestin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.